Abstract
Several observations in mice and in humans have collectively laid the foundation for examining the potential of γ δ T cells to exert tumor immunotherapy. Human γ δ T cells can be activated in a non-MHC dependent fashion either by low molecular mass phosphoantigens, or by agents that provoke the accumulation of endogenous pyrophosphates such as isopentenylpyrophosphate. Among the latter, aminobisphosphonates are well-established in the clinic, and extensive data are available on the compounds antiangiogenic, antiosteolytic and pro-apoptotic properties. In this review we discuss on the possibility that the intentional activation of γ δ T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in patients with different types of cancer.
Keywords: Human γ δ T cells, tumors, phosphoantigens, bisphosphonates, immunotherapy
Current Medicinal Chemistry
Title: Aminobisphosphonates as New Weapons for γ δ T Cell-Based Immunotherapy of Cancer
Volume: 15 Issue: 12
Author(s): Nadia Caccamo, Serena Meraviglia, Giuseppe Cicero, Gaspare Gulotta, Francesco Moschella, Adriana Cordova, Eliana Gulotta, Alfredo Salerno and Francesco Dieli
Affiliation:
Keywords: Human γ δ T cells, tumors, phosphoantigens, bisphosphonates, immunotherapy
Abstract: Several observations in mice and in humans have collectively laid the foundation for examining the potential of γ δ T cells to exert tumor immunotherapy. Human γ δ T cells can be activated in a non-MHC dependent fashion either by low molecular mass phosphoantigens, or by agents that provoke the accumulation of endogenous pyrophosphates such as isopentenylpyrophosphate. Among the latter, aminobisphosphonates are well-established in the clinic, and extensive data are available on the compounds antiangiogenic, antiosteolytic and pro-apoptotic properties. In this review we discuss on the possibility that the intentional activation of γ δ T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in patients with different types of cancer.
Export Options
About this article
Cite this article as:
Caccamo Nadia, Meraviglia Serena, Cicero Giuseppe, Gulotta Gaspare, Moschella Francesco, Cordova Adriana, Gulotta Eliana, Salerno Alfredo and Dieli Francesco, Aminobisphosphonates as New Weapons for γ δ T Cell-Based Immunotherapy of Cancer, Current Medicinal Chemistry 2008; 15 (12) . https://dx.doi.org/10.2174/092986708784310468
DOI https://dx.doi.org/10.2174/092986708784310468 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of Micro-RNA Levels, Apoptosis and Oxidative Stress Markers in Patients Recieving Chemotherapy
Combinatorial Chemistry & High Throughput Screening Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer
Current Drug Targets Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Current Pharmaceutical Biotechnology Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Current Medicinal Chemistry Cetuximab: Its Use in Combination with Radiation Therapy and Chemotherapy in the Multimodality Treatment of Head and Neck Cancer
Recent Patents on Anti-Cancer Drug Discovery Molecular Mechanisms Underlying St. Johns Wort Drug Interactions
Current Drug Metabolism Recent Advances and Approaches in Targeting Apoptosis Signaling Pathways for Anti-Cancer Therapeutics
Current Cancer Therapy Reviews Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Personalized Peptide Vaccine for Treatment of Advanced Cancer
Current Medicinal Chemistry Applications and Modifications of 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid (Tic) in Peptides and Peptidomimetics Design and Discovery
Current Protein & Peptide Science Current Application of Quantum Dots (QD) in Cancer Therapy: A Review
Mini-Reviews in Medicinal Chemistry Angiogenesis and the Heart
Recent Patents on Cardiovascular Drug Discovery Review of Dose-intense Platinum and/or Paclitaxel Containing Chemotherapy in Advanced and Recurrent Epithelial Ovarian Cancer
Current Pharmaceutical Design In Vitro and In Vivo Evaluation of [99mTc(CO)3]-Radiolabeled ErbB-2-Targeting Peptides for Breast Carcinoma Imaging
Current Radiopharmaceuticals Role of Imaging in Testicular Cancer
Current Medical Imaging Exosomal MicroRNAs in Tumoral U87 MG Versus Normal Astrocyte Cells
MicroRNA Personalized Medicine in Oncology: A Personal View with Myths and Facts
Current Clinical Pharmacology DNAzyme Delivery Approaches in Biological Settings
Current Medicinal Chemistry Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews